Amer Issa, MD
Endocrinology, Diabetes & Metabolism · Saginaw, MINPI 1326302712
Payments from drug & device makers
Across 718 payments — averaging $65.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$38K
- Lilly USA, LLC$970
- Corcept Therapeutics$968
- Tandem Diabetes Care, Inc.$746
- Sanofi-aventis U.S. LLC$648
- Boehringer Ingelheim$559
- plus $5K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 228 | $38,199 |
| Lilly USA, LLC | 67 | $970 |
| Corcept Therapeutics | 61 | $968 |
| Tandem Diabetes Care, Inc. | 44 | $746 |
| Sanofi-aventis U.S. LLC | 33 | $648 |
| Boehringer Ingelheim | 30 | $559 |
| AstraZeneca(2 entities) | 26 | $539 |
| Amgen(2 entities) | 27 | $524 |
| Medtronic(2 entities) | 25 | $464 |
| Insulet Corporation | 24 | $434 |
| Abbott | 22 | $411 |
| Dexcom, Inc. | 21 | $381 |
| Xeris Pharmaceuticals, Inc. | 18 | $322 |
| AbbVie | 17 | $317 |
| Radius Health, Inc. | 12 | $218 |
| Antares Pharma, Inc. | 11 | $198 |
| Bayer | 8 | $156 |
| Ascendis Pharma Endocrinology Inc | 5 | $112 |
| BETA Bionics, Inc. | 4 | $110 |
| IBSA Pharma Inc. | 6 | $93 |
| Recordati_rare_diseases_inc. | 4 | $82 |
| Ultragenyx Pharmaceutical Inc. | 2 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $63 |
| Tolmar, Inc. | 3 | $45 |
| Johnson & Johnson | 3 | $38 |
| Alvogen Inc | 2 | $37 |
| Cequr Corporation | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Pfizer | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Merck | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Companion Medical, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
How this compares
$46,943 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Saginaw
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.